Celularity's Cash Dries Up Amidst Declining Sales, Mounting Debt

TL;DR

**Celularity is burning cash faster than it can sell products, making it a high-risk bet with substantial doubt about its ability to survive.**

AI Summary

Celularity Inc. (CELUW) reported a net loss of $19.754 million for the three months ended March 31, 2025, a slight improvement from the $22.013 million net loss in the prior-year period. Total revenues decreased to $11.426 million from $14.681 million year-over-year, primarily driven by a decline in product sales from $12.843 million to $9.018 million. Operating expenses remained relatively stable at $21.912 million compared to $22.057 million, with a notable reduction in research and development expenses from $5.843 million to $3.728 million. The company's cash and cash equivalents significantly decreased from $738 thousand at December 31, 2024, to $293 thousand at March 31, 2025. A substantial loss on debt extinguishment of $5.736 million was recorded in Q1 2025, alongside a significant increase in warrant liabilities from $3.264 million to $8.067 million. The company's accumulated deficit grew to $919.501 million, and total stockholders' deficit reached $5.506 million, indicating severe financial distress and raising substantial doubt about its ability to continue as a going concern.

Why It Matters

Celularity's precarious financial position, marked by a negative stockholders' equity of $5.506 million and rapidly dwindling cash reserves, signals significant risk for investors. The decline in product sales and the substantial loss on debt extinguishment highlight operational challenges and a struggle to generate sustainable revenue. This could impact the company's ability to fund crucial R&D for its cellular therapy candidates, potentially delaying or halting promising treatments. For employees, this raises concerns about job security, while customers and the broader market face uncertainty regarding the long-term viability of Celularity's biomaterials and future therapeutic offerings, especially given intense competition in the biotech sector.

Risk Assessment

Risk Level: high — Celularity's risk level is high due to its negative stockholders' equity of $5.506 million as of March 31, 2025, and a significant decrease in cash and cash equivalents from $738 thousand to $293 thousand in just three months. The company explicitly states, "There is substantial doubt about our ability to continue as a going concern," directly indicating severe liquidity issues and financial instability.

Analyst Insight

Investors should avoid Celularity Inc. (CELUW) given the explicit 'going concern' warning, negative stockholders' equity, and declining revenues. Existing investors should consider divesting to mitigate further losses, as the company's ability to fund operations and R&D is severely compromised.

Financial Highlights

debt To Equity

N/A

revenue

$11.426M

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

-$19.754M

eps

N/A

gross Margin

N/A

cash Position

$293K

revenue Growth

-22.2%

Revenue Breakdown

Key Numbers

• $19.754M — Net Loss (Q1 2025 net loss, compared to $22.013M in Q1 2024)
• $11.426M — Total Revenues (Q1 2025 total revenues, a decrease from $14.681M in Q1 2024)
• $9.018M — Product Sales (Q1 2025 product sales, a decline from $12.843M in Q1 2024)
• $293K — Cash and Cash Equivalents (As of March 31, 2025, a significant drop from $738K at Dec 31, 2024)
• $5.736M — Loss on Debt Extinguishment (Recorded in Q1 2025, indicating financial restructuring costs)
• $8.067M — Warrant Liabilities (As of March 31, 2025, an increase from $3.264M at Dec 31, 2024)
• $919.501M — Accumulated Deficit (As of March 31, 2025, indicating substantial historical losses)
• $(5.506M) — Total Stockholders' (Deficit) Equity (As of March 31, 2025, indicating negative equity and severe financial distress)
• $3.728M — Research and Development Expenses (Q1 2025 R&D expenses, a decrease from $5.843M in Q1 2024)
• $2,993K — Net Cash Used in Operating Activities (Q1 2025, indicating continued cash burn from operations)

Key Players & Entities

• Celularity Inc. (company) — registrant of the 10-Q filing
• Nasdaq Stock Market LLC (regulator) — exchange where CELU and CELUW are registered
• U.S. Food and Drug Administration (regulator) — regulatory body for therapeutic candidates
• Center for Medicare & Medicaid Services (regulator) — rejected claims for Interfyl
• Yorkville (company) — recipient of common stock for debt extension and SEPA commitment fee
• Dragasac (company) — involved in warrant repricing and inducement
• C.V. Starr (company) — involved in issuance and modification of warrants
• $19.754 million (dollar_amount) — net loss for Q1 2025
• $11.426 million (dollar_amount) — total revenues for Q1 2025
• $5.736 million (dollar_amount) — loss on debt extinguishment in Q1 2025

FAQ

Risk Factors

• Going Concern Uncertainty [high — financial]: The company's accumulated deficit reached $919.501 million and total stockholders' deficit was $(5.506) million as of March 31, 2025. Cash and cash equivalents plummeted to $293 thousand from $738 thousand in just three months, indicating severe financial distress and raising substantial doubt about its ability to continue as a going concern.
• Significant Debt Extinguishment Loss [high — financial]: A substantial loss on debt extinguishment of $5.736 million was recorded in Q1 2025. This indicates significant costs associated with financial restructuring or debt repayment activities, further straining the company's financial position.
• Increasing Warrant Liabilities [medium — financial]: Warrant liabilities increased significantly from $3.264 million at December 31, 2024, to $8.067 million at March 31, 2025. This increase suggests potential future dilution and increased financial obligations as warrants are exercised.
• Declining Revenue and Product Sales [high — operational]: Total revenues decreased to $11.426 million from $14.681 million year-over-year, primarily driven by a decline in product sales from $12.843 million to $9.018 million. This trend indicates challenges in commercializing products or market demand.
• High Cash Burn Rate [high — financial]: Net cash used in operating activities was $2.993 million in Q1 2025, coupled with a drastic reduction in cash and cash equivalents to $293 thousand. This high burn rate, without sufficient cash reserves, poses an immediate liquidity risk.
• Reduced Research and Development Investment [medium — financial]: Research and development expenses decreased from $5.843 million in Q1 2024 to $3.728 million in Q1 2025. While intended to manage costs, a significant reduction in R&D could impact future product development and long-term competitiveness.

Industry Context

The biotechnology and cell therapy sector is characterized by high research and development costs, long product development cycles, and significant regulatory hurdles. Companies often rely on substantial funding to advance their pipelines, facing intense competition and the risk of clinical trial failures. Market sentiment can be volatile, heavily influenced by clinical trial results and regulatory approvals.

Regulatory Implications

Celularity operates in a highly regulated industry (biotechnology/cell therapy) requiring stringent adherence to FDA and other global health authority guidelines for product development, manufacturing, and commercialization. Failure to comply can lead to significant delays, fines, or product recalls, impacting financial performance and market access.

What Investors Should Do

1. Monitor cash runway closely.
2. Scrutinize future R&D spending.
3. Evaluate the impact of warrant liabilities.
4. Assess the sustainability of product sales.

Glossary

Accumulated Deficit

The total cumulative net losses of a company since its inception that have not been offset by net income or capital contributions. (Celularity's accumulated deficit of $919.501 million highlights its history of significant losses and its ongoing struggle to achieve profitability.)

Stockholders' Deficit

Occurs when a company's liabilities exceed its assets, resulting in negative equity for its shareholders. (Celularity's total stockholders' deficit of $(5.506) million indicates that the company owes more than it owns, a critical sign of financial distress.)

Debt Extinguishment

The process of retiring or paying off debt before its scheduled maturity date. (The $5.736 million loss on debt extinguishment suggests the company incurred significant costs to settle its debts, likely as part of a restructuring effort.)

Warrant Liabilities

Represents the fair value of financial instruments that give the holder the right, but not the obligation, to purchase a company's stock at a specified price within a certain timeframe. (The increase in warrant liabilities to $8.067 million indicates a potential future dilution of equity and an increase in financial obligations for Celularity.)

Going Concern

An accounting assumption that a business will continue to operate for the foreseeable future, typically at least 12 months. (The substantial doubt raised about Celularity's ability to continue as a going concern is a critical warning to investors about the company's immediate survival prospects.)

Year-Over-Year Comparison

Celularity Inc. reported a net loss of $19.754 million for Q1 2025, a slight improvement from $22.013 million in the prior year, but total revenues declined by 22.2% to $11.426 million, driven by a significant drop in product sales. Operating expenses remained stable, with a notable reduction in R&D, but the company's cash position has critically deteriorated to $293 thousand, and it recorded a substantial loss on debt extinguishment. New risks related to increased warrant liabilities and continued going concern uncertainty are prominent.

Key Financial Figures

• $0.0001 — tered Class A Common Stock, par value $0.0001 per share CELU The Nasdaq Stock Mar
• $115 — Common Stock at an exercise price of $115 per share CELUW The Nasdaq Stock Ma

Filing Documents

• form10-q.htm (10-Q) — 1793KB
• ex31-1.htm (EX-31.1) — 19KB
• ex31-2.htm (EX-31.2) — 20KB
• ex32-1.htm (EX-32.1) — 10KB
• ex32-2.htm (EX-32.2) — 10KB
• 0001641172-25-026056.txt ( ) — 11643KB
• celu-20250331.xsd (EX-101.SCH) — 108KB
• celu-20250331_cal.xml (EX-101.CAL) — 87KB
• celu-20250331_def.xml (EX-101.DEF) — 556KB
• celu-20250331_lab.xml (EX-101.LAB) — 763KB
• celu-20250331_pre.xml (EX-101.PRE) — 654KB
• form10-q_htm.xml (XML) — 1852KB

Financial Statements

Financial Statements 1 Unaudited Condensed Consolidated Balance Sheets 1 Condensed Consolidated Statements of Operations and Comprehensive Loss 2 Condensed Consolidated Statements of Changes In Stockholders' (Deficit) Equity 3 Condensed Consolidated Statements of Cash Flows 4 Notes to Unaudited Condensed Consolidated Financial Statements 5 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 37 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 44 Item 4.

Controls and Procedures

Controls and Procedures 44 PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 46 Item 1A.

Risk Factors

Risk Factors 47 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 47 Item 3. Defaults Upon Senior Securities 47 Item 4. Mine Safety Disclosures 47 Item 5. Other Information 47 Item 6. Exhibits 47

Signatures

Signatures 48 Unless the context indicates otherwise, references in this quarterly report to the "Company," "Celularity," "we," "us," "our" and similar terms refer to Celularity Inc. and its consolidated subsidiaries. The Celularity logo, Celularity IMPACT, Biovance, Interfyl, Lifebank, CentaFlex and other trademarks or service marks of Celularity Inc. appearing in this quarterly report are the property of Celularity Inc. This quarterly report on Form 10-Q also contains registered marks, trademarks and trade names of other companies. All other trademarks, registered marks and trade names appearing herein are the property of their respective holders. i SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS Some of the statements contained in this quarterly report on Form 10-Q, including the section entitled "Management's Discussion and Analysis of Financial Condition and Results of Operations," constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, or the Exchange Act. Forward-looking statements relate to expectations, beliefs, projections, future plans and strategies, anticipated events or trends and similar expressions concerning matters that are not historical facts. These statements relate to our future events, including our anticipated operations, research, development and commercialization activities, clinical trials, operating results and financial condition. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements, to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Forward-looking statements may include, but are not limited to, express or implied statements about: the success, cost, timing and potential indications of our cellul

View Full Filing

View this 10-Q filing on SEC EDGAR